Friday, November 14, 2025 5:55:27 PM
Solid Q for sure in regards to company health!
Anyone know why general and admin expenses went up 1.8 mill vs previous qtr? States it was head count, and increase cost of financial, tax or other regulatory compliance!!!!!
I don’t think we hired that many people this Q to have an impact on that 1.8 million, so of the other options what would we have spent it on????
Uplist prep? M&A ?
Sure seems like a 75% increase here from previous Q is huge amount of $ to spend…..
Thoughts?
Overall ELTP is strong and moving right along… also notice we went from 2 suppliers to 3, and also from 2 account receivable companies who owed us to 3…
In general still very happy for us all!!!!
Stay Slippery, people will try to shake your shares loose but don’t let them! The 10q is full of great info for company, gross profit for first 2 q was 54% vs 44% for 2024… don’t let people scare you with that, add back in this mystery 3.2 million and what would it have been???
Anyone know why general and admin expenses went up 1.8 mill vs previous qtr? States it was head count, and increase cost of financial, tax or other regulatory compliance!!!!!
I don’t think we hired that many people this Q to have an impact on that 1.8 million, so of the other options what would we have spent it on????
Uplist prep? M&A ?
Sure seems like a 75% increase here from previous Q is huge amount of $ to spend…..
Thoughts?
Overall ELTP is strong and moving right along… also notice we went from 2 suppliers to 3, and also from 2 account receivable companies who owed us to 3…
In general still very happy for us all!!!!
Stay Slippery, people will try to shake your shares loose but don’t let them! The 10q is full of great info for company, gross profit for first 2 q was 54% vs 44% for 2024… don’t let people scare you with that, add back in this mystery 3.2 million and what would it have been???
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
